RT Journal Article
SR Electronic
T1 Normalization of Cerebral Blood Flow, Neurochemicals, and White Matter Integrity After Kidney Transplantation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.04.20091199
DO 10.1101/2020.05.04.20091199
A1 Lepping, Rebecca J.
A1 Montgomery, Robert N.
A1 Sharma, Palash
A1 Mahnken, Jonathan D.
A1 Vidoni, Eric D.
A1 Choi, In-Young
A1 Sarnak, Mark J.
A1 Brooks, William M.
A1 Burns, Jeffrey M.
A1 Gupta, Aditi
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.04.20091199.abstract
AB Background Chronic kidney disease (CKD) is associated with abnormalities in cerebral blood flow (CBF), cerebral neurochemical concentrations and white matter integrity, each of which are associated with adverse clinical consequences in the non-CKD population, and may explain the high prevalence of dementia and stroke in end stage kidney disease (ESKD). Since cognition improves after kidney transplantation (KT), we examined these brain abnormalities pre-to post-KT to identify potential reversibility in ESKD-associated brain abnormalities.Methods We measured the effects of KT on CBF assessed by arterial spin labeling, cerebral neurochemical concentrations (N-acetylaspartate, choline, glutamate and glutamine, myoinositol and total creatine) measured by magnetic resonance spectroscopic imaging, and white matter integrity measured by fractional anisotropy (FA) and mean diffusivity (MD) with diffusion tensor imaging. We used a linear mixed model analysis to compare longitudinal, repeated brain MRI measurements pre-KT, and 3 months and 12 months post-KT, and also compared findings with healthy controls.Results 29 ESKD patients and 19 age-matched healthy controls participated in the study. 22 patients underwent post-KT MRI. CBF, which was higher pre-KT than in controls (p=0.003), decreased post-KT (p<0.0001) to values in controls. KT also normalized concentrations of osmotic neurochemicals choline (p<0.0001) and myo-inositol (p=0.0003) that were higher pre-KT compared to controls. Post-KT, FA increased (p=0.001) and MD decreased (p=0.0001).Conclusions Brain abnormalities in CKD are reversible and normalize with KT. Further studies are needed to understand the mechanisms underlying these brain abnormalities and to explore interventions to mitigate them even in patients who cannot be transplanted.Significance statement Kidney disease is accompanied by brain structural and physiological abnormalities and increased risk of dementia and stroke. Renal replacement therapy with dialysis does not normalize these brain abnormalities. We evaluated these brain abnormalities before and after kidney transplantation and demonstrated that unlike dialysis, kidney transplantation normalizes cerebral blood flow, neurochemical concentrations and white matter integrity. These changes persist beyond initial post-transplantation period and thus cannot be attributed to peri-procedural interventions like steroids. These results indicate reversibility of brain abnormalities in kidney disease. Further studies are needed to understand the mechanisms underlying these abnormalities and explore interventions for prevention and mitigation in patients who cannot be transplanted.Competing Interest StatementA.G. has consultancy agreement with Novartis pharmaceuticals, has funding support from Novartis and Veloxis Pharmaceuticals and is on the regional medical advisory board for the National Kidney Foundation. E.D.V. is a stakeholder in a provisional patent for measuring cerebral blood flow. M.J.S. is in the Steering Committee of a trial funded by Akebia, attended an advisory board for Bayer and is a consultant for Cardurian (none are relevant to the current manuscript).Clinical TrialNCT01883349Funding StatementThis work was supported by National Institutes of Health (NIH) grant K23 AG055666 (to A.G.), the University of Kansas Medical Center Jared Grantham Kidney Institute Pilot Grant (to A.G.), NIH Clinical and Translational Science Award grant UL1 TR002366 (to the University of Kansas Medical Center), NIH grants P30 AG035982 (to the University of Kansas Alzheimer’s Disease Center), P30 DK106912 (to the University of Kansas Medical Center Jared Grantham Kidney Institute), R21 AG061549 (to E.D.V.) and S10 RR29577 (to W.M.B.), and a gift from Forrest and Sally Hoglund (to Hoglund Biomedical Imaging Center).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available by request from the corresponding author (A.G.).